How are countries handling access to GLP-1 weight-loss drugs like Ozempic?

Access to GLP-1 weight-loss drugs varies globally; some countries like England are phasing them in slowly due to cost, while others like the UAE rely on private insurance or out-of-pocket payments.

What is the main barrier to accessing weight-loss drugs in India?

In India, the high price of GLP-1 weight-loss drugs remains a major barrier, though the advent of lower-cost generics may soon improve affordability.

Could GLP-1 weight-loss drugs save healthcare systems money in the long run?

Yes, if these GLP-1 weight-loss drugs can effectively prevent conditions like diabetes, heart attacks, and strokes, they may lead to long-term savings for healthcare systems.

Home / Business and Economy / Weight-Loss Drugs: A Global Affordability Crisis?

Weight-Loss Drugs: A Global Affordability Crisis?

3 Mar

•

Summary

GLP-1 drugs like Ozempic are reshaping obesity treatment worldwide.
Access to these costly injections varies significantly by country.
High prices pose a major barrier for many seeking weight-loss treatments.

Weight-Loss Drugs: A Global Affordability Crisis?

GLP-1 medications, including prominent drugs like Ozempic and Wegovy, are transforming obesity management internationally. Despite being deemed cost-effective by some health systems, their accessibility is frequently limited by what individuals can afford.

In England, the National Health Service recognizes the value of these treatments but faces slow rollout due to cost and capacity constraints. Meanwhile, in the United Arab Emirates, patients typically depend on private insurance or personal funds for these injections.